1. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1): 5 - 16.

2. Пушкарь Д.Ю., Раснер П.И. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы. // Урология 2006; N 3 (приложение): с. 4 - 18.

3. Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int. 2008; 102: 981 - 6.

4. Management of Non-neurogenic Male LUTS. European Association of Urology Guidelines. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts

5. Management of Benign Prostatic Hyperplasia. American Urological Association Guidelines. https://www.auanet.org/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)

6. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; N 21(2): 167 - 78.

7. Аденома простаты. Урология. Национальное руководство. Ред. Н.А. Лопаткин. М.: Гэотар-Медиа, 2009; с. 852 - 889.

8. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; N 132 (3): 474 - 479.

9. Lytton B., Emery J.M., Harvard B.M. The incidence of benign prostatic hypertrophy. J Urol 1968; N 99 (5): 639 - 645.

10. Сивков А.В. Значение ультразвуковых исследований органов мочеполовой системы при профилактических осмотрах. Диссертация канд. мед. наук., М., 1998, с. 1 - 279.

11. Abrams P, de la Rosette J, Griffiths D, Koyanagi T., Nordling J., Park Y-C., Schafer W., Zimmern P. The diagnosis of bladder outlet obstruction: Urodynamics. In: Cockett AT, Khouri S, Aso Y, Chatelain C., Denis L., Griffiths K., Murphy G. (eds). Proceedings of the 3rd International Consultation on BPH. Paris, SCI, 1995, с. 299 - 356.

12. Torlakovic G., Grover V.K., Torlakovic E. Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume. Croat Med J 2005; N 46 (3): 423 - 428.

13. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., Coyne K., Kelleher C., Hampel C., Artibani W., Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; N 50 (6): 1306 - 14.

14. Chapple C., Abrams P. Lower Urinary Tract Symptoms. In: Male Lower Urinary Tract Symptoms (LUTS). Editors Societe Internationale d'Urologie (SIU). Fukuoka, Japan, 2012. p. 44 - 60.

15. Taoka R., Kakehi Y. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol 2017; N 4 (3): 158 - 163.

16. Ezz el Din K., Kiemeney L.A., de Wildt M.J., Debruyne F.M., de la Rosette J.J. Correlation between uroflowmetry, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996; N 48 (3): 393 - 397.

17. Barry M.J., Fowler F.J. Jr., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L, Mebust W.K., Cockett A.T. The American Urological Association symptom index for benign prostatic hyperplasia. The Committee of the American Urological Association. J Urol 1992; N 148 (5): 549 - 57.

18. D'Silva K.A., Dahm P., Wong C.L. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA 2014; N 312 (5): 535 - 42.

19. Milsom I., Abrams P., Cardozo L., Roberts R.G., J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; N 87 (9): 760 - 6.

20. Tikkinen K.A., Johnson T.M. Tammela T.L. Sintonen H., Haukka J., Huhtala H., Auvinen A. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2010; N 57 (3): 488 - 496.

21. Van Venrooij G.E., Eckhardt M.D., Gisholf K.W., Boon T.A. Data from frequency-volume charts versus symptom scores and quality of life score in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2001; N 39 (1): 42 - 47.

22. Yap T.L., Cromwell D.C., Emberton M. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int 2007; N 99 (1): 9 - 16.

23. Cornu J.N., Abrams P., Chapple C.R., Dmochowski R.R., Lemack G.E., Michel M.C., Tubaro A., Madersbacher S. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management - a systematic review and meta-analysis. Eur Urol 2012; N 62 (5): 877 - 90.

24. Bosch J.L., Bohnen A.M., Groeneveld F.P. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004; N 46 (6): 573 - 9.

25. Weissfeld J.L., Fagerstrom R.M., O"Brien B.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; N 21 (6 Suppl): 390 - 9.

26. Dong F., Kattan M.W., Steyerberg E.W., Jones J.S., Stephenson A.J., F.H., Klein E.A. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; N 180(1): 150 - 4.

27. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; N 279 (19): 1542 - 7.

28. Carvalhal G.F., Smith D.S., Mager D.E., Ramos C., Catalona W.J. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999; N 161 (3): 835 - 9.

29. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., DeKernion J.B., Ratliff T.L., Kavoussi L.R.. Dalkin B.L, Waters W.B., MacFarlane M.T., Southwick P.C. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; N 151 (5): 1283 - 90.

30. Bohnen A.M., Groeneveld F.P., Bosch J.L. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007; N 51 (6): 1645 - 52.

31. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L. Jr., Dixon C.M., Kusek J.W., Lepor H., McVary K.T., Nyberg L.M. Jr., Clarke H.S., Crawford E.D., Diokno A., Foley J.P., Foster H.E., Jacobs S.C., Kaplan S.A., Kreder K.J., Lieber M.M., Lucia M.S., Miller G.J., Menon M., Milam D.F., Ramsdell J.W., Schenkman N.S., Slawin K.M., Smith J.A.; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; N 349 (25): 2387 - 98.

32. Lim K.B., Ho H., Foo K.T., Wong M.Y., Fook-Chong S. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol 2006; N 13 (12): 1509 - 13.

33. Abrams P., Chapple C., Khoury S., Roehrborn C., de la Rosette J.; International Consultation on New Developments in Prostate Cancer and Prostate Diseases. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2013; N 189 (1Suppl): S93 - S101.

34. Gerber G.S., Goldfischer E.R., Karrison T.G., Bales G.T. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 1997; N 49 (5): 697 - 702.

35. Rule A.D., Jacobson D.J., Roberts R.O., Girman C.J., McGree M.E., Lieber M.M., Jacobsen S.J. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int 2005; N 67 (6): 2376 - 82.

36. Lee J.H., Kwon H., Park Y.W., Cho I.C., Min S.K. Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms. Urology 2013; N 82 (6): 1381 - 5.

37. Hong S.K., Lee S.T., Jeong S.J., Byun S.S., Hong Y.K., Park D.S., Hong J.Y., Son J.H., Kim C., Jang S.H., Lee S.E. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int 2010; N 105 (10): 1424 - 8.

38. Oelke M., Kirschner-Hermanns R., Thiruchelvam N., Heesakkers J. Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011. Neurourol Urodyn 2012; N 31 (3): 322 - 6.

39. Mebust W.K., Holtgrewe H.L., Cockett A.T., Peters P.C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; N 141 (2): 243 - 7.

40. Grossfeld, G.D., Coakley F.V. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am 2000; N 38 (1): 31 - 47.

41. Roehrborn C.G., Bartsch G., Kirby R., Andriole G., Boyle P., de la Rosette J., Perrin P., Ramsey E., Nordling J., De Campos Freire G., Arap S. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; N 58 (5): 642 - 50.

42. Rule A.D., McGree M.E., Girman C.J., Lieber M.M., Jacobsen S.J. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol 2005; N 174 (Pt 1): 1317 - 21.

43. Sullivan M.P., Yalla S.V. Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol 1996; N 155 (6): 1995 - 2000.

44. Oelke M., K., Jonas U., de la Rosette J.J., Ubbink D.T., Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol 2007; N 52 (3): 827 - 34.

45. Mochtar C.A., Kiemeney L.A., van Riemsdijk M.M., Laguna M.P., Debruyne F.M., de la Rosette J.J. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol 2006; N 175 (1): 213 - 6.

46. Каприн А.Д., Аполихин О.И., Сивков А.В., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за период 2002 - 2014 гг. по данным официальной статистики. Экспериментальная и клиническая урология 201; N (3): 4 - 16.

47. Jorgensen J.B., Jensen K.M., Mogensen P. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br J Urol 1992; N 69 (3): 265 - 71.

48. Kranse R., van Mastrigt R. Causes for variability in repeated pressure-flow measurements. Urology 2003; N 61 (5): 930 - 4.

49. Idzenga, T., Pel J.J., van Mastrigt R. Accuracy of maximum flow rate for diagnosing bladder outlet obstruction can be estimated from the ICS nomogram. Neurourol Urodyn 2008; N 27 (1): 97 - 8.

50. Reynard J.M., Yang Q., Donovan J.L., Peters T.J., Schafer W., de la Rosette J.J., Dabhoiwala N.F., Osawa D., Lim A.T., Abrams P. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; N 82 (5): 619 - 23.

51. Oh M.M., Choi H., Park M.G., Kang S.H., Cheon J., Bae J.H., Moon du G., Kim J.J., Lee J.G. Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction? Urology 2011; N 77 (1): 167 - 70.

52. Jeong S.J., Kim H.J., Lee Y.J., Lee J.K., Lee B.K., Choo Y.M., Oh J.J., Lee S.C., Jeong C.W., Yoon C.Y., Hong S.K., Byun S.S., Lee S.E. Prevalence and Clinical Features of Detrusor Underactivity among Elderly with Lower Urinary Tract Symptoms: A Comparison between Men and Women. Korean J Urol 2012; N 53 (5): 342 - 8.

53. Thomas A.W., Cannon A., Bartlett E., Ellis-Jones J., Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004; N 93 (6): 745 - 50.

54. Clement K., Burden H., Warren K., Lapitan M., Omar M., Drake M. Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction. Cochrane Database Syst Rev, 2015: CD011179.

55. Stohrer M., Blok B., Castro-Diaz D., Chartier-Kastler E., Del Popolo G., Kramer G., Pannek J., Radziszewski P., Wyndaele J.J. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; N 56 (1): 81 - 8.

56. el Din K.E., Kiemeney LA., de Wildt M.J., Rosier P.F., Debruyne F.M., de la Rosette J.J. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol 1996; N 156 (3): 1020 - 5.

57. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009 Nov; 36(4): 403 - 15.

58. Brown, C.T., et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. Bmj, 2007. 334: 25.

59. Yang, Dae Yul; Lee, Won Ki (2019). A current perspective on post-micturition dribble in males. Investigative and Clinical Urology, 60(3), 142 - 148

60. Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, Rwabasonga B, Risk MC, Wilt TJ Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol. 2017 Apr; 71(4): 570 - 581.

61. Woo H.H., Gillman M.P., Gardiner R., Marshall V., Lynch W.J. A practical approach to the management of lower urinary tract symptoms among men. Med J Aust. 2011 Jul 4; 195(1): 34 - 9.

62. Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2017; 11: CD012615.

63. Park T, Choi JY. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World J Urol 2014; 32: 1093 - 105.

64. Jae Heon Kim, Min Jung Baek, Hwa Yeon Sun, Bora Lee, Shufeng Li, Yash Khandwala, Francesco Del Giudice, Benjamin I. Chung Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One. 2018; 13(10): e0203479.

65. Naslund MJ, Miner M. A review of the clinical efficacy and safety of -reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29: 17 - 25.

66. Roehrborn CG. -reductase inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol 2003; 5 Suppl 5: S12 - 21.

67. Roehrborn CG, Siami P, Barkin J, R, Major-Walker K, Nandy I, et al. CombAT Study Group The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123 - 31.

68. Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol 2017; 6: 295 - 304.

69. Favilla V, Russo GI, Privitera S, Castelli T, Giardina R, Calogero AE, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male 2016; 19: 175 - 81.

70. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving -reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868 - 74.

71. Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014; 191: 1003 - 8.

72. Gillian Yeowell, 1 Philip Smith, 1 Jameel Nazir, 2 Zalmai Hakimi, 3 Emad Siddiqui, 2 and Francis Fatoye Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018; 8(11): e021889.

73. Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65: 567 - 85.

74. Chapple, C.R., et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and effi cacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 2013. 63: 296.

75. Herschorn, S., et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the effi cacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology, 2013. 82: 313.

76. Kuo, H.C., et al. Results of a randomized, double-blind, parallel-group, placebo- and activecontrolled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn, 2015. 34: 685

77. Nitti, V.W., et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol, 2013. 190: 1320.

78. Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016; 32(4): 621 - 38.

79. Giuliano F., et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia // Eur. Urol. - 2013. - Vol. 63. - P. 506 - 616

80. Morelli A., et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats // J. Sex. Med. - 2011. - Vol. 8. - P. 2746 - 2760.

81. Vignozzi L., et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS // Prostate. - 2013. - Vol. 73. - P. 1391 - 1402.

82. Ji Eon Won, Ji Yeon Chu, Hyunah Caroline Choi, Yun Chen, Hyun Jun Park, . Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study. World J Mens Health. 2018 May; 36(2): 161 - 170.

83. Hyun Jun Park, Ji Eon Joanne Won, Sebastian Sorsaburu, Paul David Rivera, and Seung Wook Lee. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health. 2013 Dec; 31(3): 193 - 207.

84. Madersbacher, S., et al. Plant extracts: sense or nonsense? Curr Opin Urol, 2008. 18: 16.

85. Buck, A.C. Is there a scientifi c basis for the therapeutic eff ects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol, 2004. 172: 1792.

86. Diaa-Eldin Taha, a, * Omar M. Aboumarzouk, b and Ahmed A. Shokeirc Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature. Arab J Urol. 2018 Dec; 16(4): 404 - 410.

87. Steven A. Kaplan, M.D., a Jeannette Y. Lee, Ph.D., b Alan G. Meehan, Ph.D., c John W. Kusek, Ph.D., d and Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Long-term Treatment with Finasteride Resulted in a Significant Improvement Relative to Placebo in Clinical Progression of Benign Prostatic Hyperplasia (BPH) in Men with Enlarged Prostates ( 30 mL), But Not in Those with Smaller Prostates (< 30 mL): Data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. *J Urol. 2011 Apr; 185(4): 1369 - 1373.

88. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM, Jr., for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group Combination therapy with doxazosin and finasteride led to a significantly greater reduction in the risk of clinical progression of BPH compared to either drug alone in LUTS patients with a baseline total prostate volume of 25 ml. J Urol. 2006; 175: 217 - 220.

89. Cheuk Fan Shum, * Weida Lau, and Chang Peng Colin Teo Medical therapy for clinical benign prostatic hyperplasia: Antagonists, reductase inhibitors and their combination. Asian J Urol. 2017 Jul; 4(3): 185 - 190.

90. van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, et al. Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial. Eur Urol. 2013 Dec; 64(6): 1003 - 12.

91. Kim HJ, Sun HY, Choi H, Park JY, Bae JH, Doo SW, et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PLoS One 2017; 12: e0169248.

92. Kaplan, S.A., et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract, 2011. 65: 487.

93. Athanasopoulos, A., et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol, 2011. 60: 94.

94. Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 2011; 108: 89 - 93.

95. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403 - 15.

96. Emberton M, Cornel E, Bassi P, Fourcade O, Go'mez M, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008; 62: 1076 - 86.

97. NICE. (2010) National Institute for Health and Clinical Excellence. The management of lower urinary tract symptoms in men & Appendices A - H: http://www.nice.org.uk/nicemedia/live/12984/48554/48554.pdf.

98. Ahyai, S.A., et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol, 2010. 58: 384 - 397.

99. Madersbacher S., et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases // Eur. Urol. - 2005. - Vol. 47. - P. 499 - 504. http://www.ncbi. nlm.nih.gov/pubmed/15774249

100. Reich O, Gratzke C, Bachmann A et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol, 2008. 180: 246.

101. Omar, M.I., et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int, 2014. 113: 24.

102. Cornu, J.N., et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol, 2015. 67: 1066.

103. Mamoulakis, C., et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev, 2014. 1

104. Autorino, R., et al. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol, 2009. 55: 922. https://pubmed.ncbi.nlm.nih.gov/19185975/

105. Chen, Q., et al. Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. BJU Int, 2010. 106: 1339. https://pubmed.ncbi.nlm.nih.gov/20477825/

106. Fagerstrom, T., et al. Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate. J Endourol, 2011. 25: 1043. https://pubmed.ncbi.nlm.nih.gov/21568691/

107. Giulianelli, R., et al. Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up. Arch Ital Urol Androl, 2013. 85: 86. https://pubmed.ncbi.nlm.nih.gov/23820656/

108. Mamoulakis, C., et al. Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate. Eur Urol, 2013. 63: 667. https://pubmed.ncbi.nlm.nih.gov/23102675/

109. Xie, C.Y., et al. Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Yonsei Med J, 2012. 53: 734. https://pubmed.ncbi.nlm.nih.gov/22665339/

110. Komura, K., et al. Incidence of urethral stricture after bipolar transurethral resection of the prostate using TURis: results from a randomised trial. BJU Int, 2015. 115: 644. https://pubmed.ncbi.nlm.nih.gov/24909399/

111. Kumar, N., et al. Prospective Randomized Comparison of Monopolar TURP, Bipolar TURP and Photoselective Vaporization of the Prostate in Patients with Benign Prostatic Obstruction: 36 Months Outcome. Low Urin Tract Symptoms, 2018. 10: 17. https://pubmed.ncbi.nlm.nih.gov/27168018/

112. Burke, N., et al. Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. Urology, 2010. 75: 1015.

113. Lourenco, T., et al. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol, 2010. 28: 23.

114. Bach, T., et al. Laser treatment of benign prostatic obstruction: basics and physical differences. Eur Urol, 2012. 61: 317. https://pubmed.ncbi.nlm.nih.gov/22033173/

115. Xia, S.J., et al. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol, 2008. 53: 382. https://pubmed.ncbi.nlm.nih.gov/17566639/

116. Jiang, H., et al. Safety and Efficacy of Thulium Laser Prostatectomy Versus Transurethral Resection of Prostate for Treatment of Benign Prostate Hyperplasia: A Meta-Analysis. Low Urin Tract Symptoms, 2016. 8: 165. https://pubmed.ncbi.nlm.nih.gov/27619781/

117. Zhang, X., et al. Different lasers in the treatment of benign prostatic hyperplasia: a network metaanalysis. Scientific reports, 2016. 6: 23503. https://pubmed.ncbi.nlm.nih.gov/27009501/96

118. Zhu, Y., et al. Thulium laser versus standard transurethral resection of the prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol, 2015. 33: 509. https://pubmed.ncbi.nlm.nih.gov/25298242/

119. Zhao, C., et al. Thulium Laser Resection Versus Plasmakinetic Resection of Prostates in the Treatment of Benign Prostate Hyperplasia: A Meta-Analysis. J Laparoen Adv Surg Tech Part A, 2016. 26: 789. https://pubmed.ncbi.nlm.nih.gov/27500451/

120. Deng, Z., et al. Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol, 2018. 36: 1355. https://pubmed.ncbi.nlm.nih.gov/29651642/

121. Lan, Y., et al. Thulium (Tm:YAG) laser vaporesection of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis. Lasers Med Sci, 2018. 33: 1411. https://pubmed.ncbi.nlm.nih.gov/29947009/

122. Hashim, H., et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomized controlled trial. The Lancet, 2020. 396: 50. https://pubmed.ncbi.nlm.nih.gov/32622397/

123. Cui, D., et al. A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results. World J Urol, 2014. 32: 683. https://pubmed.ncbi.nlm.nih.gov/23913094/

124. Sun, F., et al. Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers. World J Urol, 2015. 33: 503. https://pubmed.ncbi.nlm.nih.gov/25487702/

125. Worthington, J., et al. Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: The UNBLOCS RCT. Health Tech Ass, 2020. 24: 1. https://pubmed.ncbi.nlm.nih.gov/32901611/

126. Yang, Z., et al. Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up. Urology, 2013. 81: 396. https://pubmed.ncbi.nlm.nih.gov/23374815/

127. Wei, H., et al. Thulium laser resection versus plasmakinetic resection of prostates larger than 80 ml. World J Urol, 2014. 32: 1077. https://pubmed.ncbi.nlm.nih.gov/24264126/

128. Sener, T.E., et al. Thulium laser vaporesection of the prostate: Can we operate without interrupting oral antiplatelet/ anticoagulant therapy? Invest Clin Urol, 2017. 58: 192. https://pubmed.ncbi.nlm.nih.gov/28480345/

129. Varkarakis, I., et al. Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology, 2004. 64: 306. https://pubmed.ncbi.nlm.nih.gov/15302484/

130. Gratzke, C., et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol, 2007. 177: 1419. https://pubmed.ncbi.nlm.nih.gov/17382744/

131. Skolarikos, A., et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol, 2008. 22: 2333.

132. Chen, S., et al. Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. Eur Urol, 2014. 66: 284. https://pubmed.ncbi.nlm.nih.gov/24502959/

133. Li, M., et al. Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. PLoS One, 2015. 10: e0121265. https://pubmed.ncbi.nlm.nih.gov/25826453/

134. Lin, Y., et al. Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World J Urol, 2016. 34: 1207. https://pubmed.ncbi.nlm.nih.gov/26699627/

135. Ou, R., et al. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes > 80 mL: a prospective randomized study. BJU Int, 2013. 112: 239. https://pubmed.ncbi.nlm.nih.gov/23795788/

136. Rao, J.M., et al. Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia > 80 mL: 12-month follow-up results of a randomized clinical trial. Urology, 2013. 82: 176. https://pubmed.ncbi.nlm.nih.gov/23601443/

137. Geavlete, B., et al. Bipolar vaporization, resection, and enucleation versus open prostatectomy: optimal treatment alternatives in large prostate cases? J Endourol, 2015. 29: 323. https://pubmed.ncbi.nlm.nih.gov/25111385/

138. Geavlete, B., et al. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases-a medium term, prospective, randomized comparison. BJU Int, 2013. 111: 793. https://pubmed.ncbi.nlm.nih.gov/23469933/

139. Salonia, A., et al. Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis. Urology, 2006. 68: 302. https://pubmed.ncbi.nlm.nih.gov/16904441/

140. Kuntz, R.M., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol, 2008. 53: 160.

141. Zhang, Y., et al. Transurethral holmium laser enucleation for prostate adenoma greater than 100 g. Zhonghua Nan Ke Xue, 2007. 13: 1091. https://pubmed.ncbi.nlm.nih.gov/18284057/

142. Neill, M.G., et al. Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. Urology, 2006. 68: 1020. https://pubmed.ncbi.nlm.nih.gov/17095078/

143. Li, K., et al. A Novel Modification of Transurethral Enucleation and Resection of the Prostate in Patients With Prostate Glands Larger than 80 mL: Surgical Procedures and Clinical Outcomes. Urology, 2018. 113: 153. https://pubmed.ncbi.nlm.nih.gov/29203184/

144. Zhao, Z., et al. A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results. Eur Urol, 2010. 58: 752. https://pubmed.ncbi.nlm.nih.gov/20800340/

145. Zhang, K., et al. Plasmakinetic Vapor Enucleation of the Prostate with Button Electrode versus Plasmakinetic Resection of the Prostate for Benign Prostatic Enlargement > 90 ml: Perioperative and 3-Month Follow-Up Results of a Prospective, Randomized Clinical Trial. Urol Int, 2015. 95: 260. https://pubmed.ncbi.nlm.nih.gov/26044933/

146. Wang, Z., et al. A prospective, randomised trial comparing transurethral enucleation with bipolar system (TUEB) to monopolar resectoscope enucleation of the prostate for symptomatic benign prostatic hyperplasia. Biomed Res, 2017. 28.

147. Ran, L., et al. Comparison of fluid absorption between transurethral enucleation and transurethral resection for benign prostate hyperplasia. Urol Int, 2013. 91: 26. https://pubmed.ncbi.nlm.nih.gov/23571450/

148. Luo, Y.H., et al. Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients. Urology, 2014. 84: 904. https://pubmed.ncbi.nlm.nih.gov/25150180/98

149. Zhu, L., et al. Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup. J Urol, 2013. 189: 1427. https://pubmed.ncbi.nlm.nih.gov/23123549/

150. Tian, J., et al. Comparative study of the effectiveness and safety of transurethral bipolar plasmakinetic enucleation of the prostate and transurethral bipolar plasmakinetic resection of the prostate for massive benign prostate hyperplasia (> 80 ml). Med Sci Monitor, 2020. 26: e921272. https://pubmed.ncbi.nlm.nih.gov/32339160/

151. Samir, M., et al. Two-year Follow-up in Bipolar Transurethral Enucleation and Resection of the Prostate in Comparison with Bipolar Transurethral Resection of the Prostate in Treatment of Large Prostates. Randomized Controlled Trial. Urology, 2019. 133: 192. https://pubmed.ncbi.nlm.nih.gov/31404581/

152. Zhang, Y., et al. Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials.ProstateCancerProstaticDis, 2019. https://pubmed.ncbi.nlm.nih.gov/30816336/

153. Arcaniolo, D., et al. Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis. World J Urol, 2020. 38: 1177. https://pubmed.ncbi.nlm.nih.gov/31346761/

154. Liu, Q.-L., et al. Comparison of the Transurethral Resection of the Prostate by Traditional Versus Preserved Urethral Mucosa of the Prostatic Apex. J Endourol, 2020. 34: 482. https://pubmed.ncbi.nlm.nih.gov/31964193/

155. Gilling, P.J., et al. Combination holmium and Nd: YAG laser ablation of the prostate: initial clinical experience. J Endourol, 1995. 9: 151. https://pubmed.ncbi.nlm.nih.gov/7633476/

156. Tan, A., et al. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg, 2007. 94: 1201. https://pubmed.ncbi.nlm.nih.gov/17729384/

157. Yin, L., et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol, 2013. 27: 604. https://pubmed.ncbi.nlm.nih.gov/23167266/

158. Qian, X., et al. Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and Meta-analysis. Aging Male, 2017. 20: 184. https://pubmed.ncbi.nlm.nih.gov/28368238/

159. Gilling, P.J., et al. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int, 2012. 109: 408. https://pubmed.ncbi.nlm.nih.gov/21883820/

160. Chen, Y.B., et al. A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol, 2013. 189: 217. https://pubmed.ncbi.nlm.nih.gov/23174256/

161. Gu, M., et al. Comparison of Holmium Laser Enucleation and Plasmakinetic Resection of Prostate: A Randomized Trial with 72-Month Follow-Up. J Endourol, 2018. 32: 139. https://pubmed.ncbi.nlm.nih.gov/29239228/

162. Elshal, A.M., et al. Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes. BJU Int, 2020. 126: 731. https://pubmed.ncbi.nlm.nih.gov/32633020/

163. Higazy, A., et al. Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial. Int J Urol, 2021. 28: 333. https://pubmed.ncbi.nlm.nih.gov/33327043/

164. Heidar, N.A., et al. Laser enucleation of the prostate versus transurethral resection of the prostate: perioperative outcomes from the ACS NSQIP database. World J Urol, 2020. 38: 2891. https://pubmed.ncbi.nlm.nih.gov/32036397/

165. Lourenco, T., et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. Bmj, 2008. 337: a449. https://pubmed.ncbi.nlm.nih.gov/18595932/

166. Huang, K.C., et al. Combination of Thulium Laser Incision and Bipolar Resection Offers Higher Resection Velocity than Bipolar Resection Alone in Large Prostates. Urol J, 2019. 16: 397. https://pubmed.ncbi.nlm.nih.gov/30318570/99

167. Bozzini, G., et al. A prospective multicenter randomized comparison between Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Laser Enucleation of the Prostate (ThuLEP). World J Urol, 2020. https://pubmed.ncbi.nlm.nih.gov/32997262/

168. El Tayeb, M.M., et al. Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation. J Endourol, 2016. 30: 805. https://pubmed.ncbi.nlm.nih.gov/27065437/

169. Sun, J., et al. Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT). World J Urol, 2018. 36: 271. https://pubmed.ncbi.nlm.nih.gov/29138929/

170. Elzayat, E.A., et al. Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol, 2007. 52: 1465. https://pubmed.ncbi.nlm.nih.gov/17498867/

171. Du, C., et al. Holmium laser enucleation of the prostate: the safety, efficacy, and learning experience in China. J Endourol, 2008. 22: 1031. https://pubmed.ncbi.nlm.nih.gov/18377236/

172. Robert, G., et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int, 2016. 117: 495. https://pubmed.ncbi.nlm.nih.gov/25781490/

173. Aho, T., et al. Description of a modular mentorship programme for holmium laser enucleation of the prostate. World J Urol, 2015. 33: 497. https://pubmed.ncbi.nlm.nih.gov/25271105/

174. Enikeev, D., et al. A Randomized Trial Comparing The Learning Curve of 3 Endoscopic Enucleation Techniques (HoLEP, ThuFLEP, and MEP) for BPH Using Mentoring Approach-Initial Results. Urology, 2018. 121: 51. https://pubmed.ncbi.nlm.nih.gov/30053397/

175. Enikeev D, et al. Novel Thulium Fiber Laser for Enucleation of Prostate: A Retrospective Comparison with Open Simple Prostatectomy. J Endourol, 2018 Nov 29. doi: 10.1089

176. Enikeev D, et al. Impact of endoscopic enucleation of the prostate with thulium fiber laser on the erectile function. BMC Urol. 2018 Oct 12; 18(1): 87. Epub 2018 Oct 12

177. Yang, Z., et al. Comparison of thulium laser enucleation and plasmakinetic resection of the prostate in a randomized prospective trial with 5-year follow-up. Lasers Med Sci, 2016. 31: 1797. https://pubmed.ncbi.nlm.nih.gov/27677474/

178. Hartung, F.O., et al. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2021. https://pubmed.ncbi.nlm.nih.gov/33840611/

179. Zhang, F., et al. Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urology, 2012. 79: 869. https://pubmed.ncbi.nlm.nih.gov/22342411/

180. Feng, L., et al. Thulium Laser Enucleation Versus Plasmakinetic Enucleation of the Prostate: A Randomized Trial of a Single Center. J Endourol, 2016. 30: 665. https://pubmed.ncbi.nlm.nih.gov/26886719/100

181. Bach, T., et al. Thulium:YAG vapoenucleation in large volume prostates. J Urol, 2011. 186: 2323. https://pubmed.ncbi.nlm.nih.gov/22014812/

182. Hauser, S., et al. Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. Urol Int, 2012. 88: 390. https://pubmed.ncbi.nlm.nih.gov/22627127/

183. Netsch, C., et al. Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. World J Urol, 2014. 32: 165. https://pubmed.ncbi.nlm.nih.gov/23657354/

184. Netsch, C., et al. Comparison of 120 - 200 W 2 thulium: yttrium-aluminum-garnet vapoenucleation of the prostate. J Endourol, 2012. 26: 224. https://pubmed.ncbi.nlm.nih.gov/22191688/

185. Becker, B., et al. Thulium vapoenucleation of the prostate (ThuVEP) for prostates larger than 85 ml: longterm durability of the procedure. Lasers Med Sci, 2019. 34: 1637. https://pubmed.ncbi.nlm.nih.gov/30838464/

186. Hanada, I., et al. Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study. Int J Urol, 2020. 27: 974. https://pubmed.ncbi.nlm.nih.gov/33241599/

187. Xiao, K.W., et al. Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis. Lasers Med Sci, 2019. https://pubmed.ncbi.nlm.nih.gov/30604345/

188. Chang, C.H., et al. Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study. BMC Urol, 2015. 15: 40. https://pubmed.ncbi.nlm.nih.gov/25956819/

189. Gross, A.J., et al. Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol, 2013. 63: 859. https://pubmed.ncbi.nlm.nih.gov/23245687/

190. Chung, D.E., et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol, 2011. 186: 977.

191. Lusuardi, L., et al. Safety and efficacy of Eraser laser enucleation of the prostate: preliminary report. J Urol, 2011. 186: 1967. https://pubmed.ncbi.nlm.nih.gov/21944122/

192. Zhang, J., et al. 1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. J Endourol, 2019. 33: 211. https://pubmed.ncbi.nlm.nih.gov/30489151/

193. Zou, Z., et al. Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results. World J Urol, 2018. https://pubmed.ncbi.nlm.nih.gov/29459994/

194. Xu, A., et al. A randomized trial comparing diode laser enucleation of the prostate with plasmakinetic enucleation and resection of the prostate for the treatment of benign prostatic hyperplasia. J Endourol, 2013. 27: 1254. https://pubmed.ncbi.nlm.nih.gov/23879477/

195. Wu, G., et al. A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up. Lasers Med Sci, 2016. 31: 599. https://pubmed.ncbi.nlm.nih.gov/26822403/

196. He, G., et al. Comparison of Diode Laser (980 nm) Enucleation vs Holmium Laser Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia: A Randomized Controlled Trial with 12-Month Follow-Up. J Endourol, 2019. 33: 843. https://pubmed.ncbi.nlm.nih.gov/31298571/

197. Mariano, M.B., et al. Laparoscopic prostatectomy with vascular control for benign prostatic hyperplasia. J Urol, 2002. 167: 2528. https://pubmed.ncbi.nlm.nih.gov/11992078/101

198. Sotelo, R., et al. Robotic simple prostatectomy. J Urol, 2008. 179: 513. https://pubmed.ncbi.nlm.nih.gov/18076926/

199. Lucca, I., et al. Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol, 2015. 33: 563. https://pubmed.ncbi.nlm.nih.gov/24879405/

200. Li, J., et al. Comparison Between Minimally Invasive Simple Prostatectomy and Open Simple Prostatectomy for Large Prostates: A Systematic Review and Meta-Analysis of Comparative Trials. J Endourol, 2019. 33: 767. https://pubmed.ncbi.nlm.nih.gov/31244334/

201. Velotti, G., et al. Holmium laser enucleation of prostate versus minimally invasive simple prostatectomy for large volume ( 120 ml) prostate glands: a prospective multicenter randomized study. Minerva Urol Nephrol, 2021. 73: 638. https://pubmed.ncbi.nlm.nih.gov/33200899/

202. Autorino, R., et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol, 2015. 68: 86. https://pubmed.ncbi.nlm.nih.gov/25484140/

203. Pokorny, M., et al. Robot-assisted Simple Prostatectomy for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement: Surgical Technique and Outcomes in a High-volume Robotic Centre. Eur Urol, 2015. 68: 451. https://pubmed.ncbi.nlm.nih.gov/25887786/

204. Sorokin, I., et al. Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. J Endourol, 2017. 31: 1164. https://pubmed.ncbi.nlm.nih.gov/28854815/

205. Huang, S.-W., et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ, 2019. 367: 15919. https://pubmed.ncbi.nlm.nih.gov/31727627/

206. Lee, S.W., et al. Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: A quality and meta-analysis. Int Neurourol J, 2013. 17: 59. https://pubmed.ncbi.nlm.nih.gov/23869269/

207. Wroclawski, M.L., et al. "Button type" bipolar plasma vaporisation of the prostate compared with standard transurethral resection: A systematic review and meta-analysis of short-term outcome studies. BJU Int, 2016. 117: 662. https://pubmed.ncbi.nlm.nih.gov/26299915/

208. Robert, G., et al. Bipolar plasma vaporization of the prostate: ready to replace GreenLight? A systematic review of randomized control trials. World J Urol, 2015. 33: 549. https://pubmed.ncbi.nlm.nih.gov/25159871/

209. Geavlete, B., et al. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. Urology, 2011. 78: 930. https://pubmed.ncbi.nlm.nih.gov/21802121/95

210. Zhou, Y., et al. Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. Lasers Med Sci, 2016. 31: 485.

211. Thomas, J.A., et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol, 2016. 69: 94. https://pubmed.ncbi.nlm.nih.gov/26283011/

212. Al-Ansari, A., et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol, 2010. 58: 349. https://pubmed.ncbi.nlm.nih.gov/20605316/

213. Pereira-Correia, J.A., et al. GreenLight HPS 120-W laser vaporization vs transurethral resection of the prostate (< 60 mL): a 2-year randomized double-blind prospective urodynamic investigation. BJU Int, 2012. 110: 1184. https://pubmed.ncbi.nlm.nih.gov/22257240/

214. Kang, D.H., et al. A Systematic Review and Meta-Analysis of Functional Outcomes and Complications Following the Photoselective Vaporization of the Prostate and Monopolar Transurethral Resection of the Prostate. World J Men's Health, 2016. 34: 110. https://www.ncbi.nlm.nih.gov/pubmed/27574594/

215. Malling B, et al. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2019 Jan; 29(1): 287 - 298.

216. Kuang M, et al. A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia. Cardiovasc Intervent Radiol. 2017 May; 40(5): 655 - 663.

217. Managing lower urinary tract symptoms in men. https://pathways.nice.org.uk/pathways/lower-urinary-tract-symptoms-in-men#path=view%3A/pathways/lower-urinary-tract-symptoms-in-men/managing-lower-urinary-tract-symptoms-in-men.xml&content=view-index

218. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN160040.pdf

219. Vanderbrink, B.A., et al. Prostatic stents for the treatment of benign prostatic hyperplasia. Curr Opin Urol, 2007. 17: 1.

220. Bapir R., Bhatti K.H., Eliwa A. et al. Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis. Arch Ital Urol Androl. 2022 Jun 30; 94(2): 252 - 263.

221. Rangganata E., Widia A. et al. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly. Acta Med Indones. 2020 Jul; 52(3): 255 - 263.

222. Wagg, A., et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin, 2016. 32: 621.

223. Wagg, A., et al. Efficacy, safety, and tolerability of mirabegron in patients aged 65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur J, 2020. 77: 211.

224. Chapple, C.R., et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur J, 2017. 72: 389.

225. Pattanaik, S., et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev, 2018. 11: CD010060.

226. EMA, Tadalafil Lilly: EPAR-Product Information, European Medicine Agency, Ed. 2017.

227. Scaglione, F., et al. Comparison of the potency of different brands of Serenoa repens extract on 5alphareductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology, 2008. 82: 270.

228. Tacklind, J., et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev, 2009: CD001423.

229. Novara, G., et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2016. 2: 553.

230. Vela-Navarrete, R., et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R))) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int, 2018. 122: 1049.

231. Rees, J., et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn, 2019. 38: 981.

232. Burgio, K.L., et al. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial. JAMA Int Med, 2020. 180: 411.

233. Ichihara, K., et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol, 2015. 193: 921.

234. Kaplan, S.A., et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol, 2020. 203: 1163.

235. Soliman, M.G., et al. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol, 2020.

236. Затевахин, И. И., Цициашвили М.Ш., Мишнев А.Д., Трусов О.А. Послеоперационные венозные тромбоэмболические осложнения насколько реальна угроза? Ангиология и сосудистая хирургия. - 2002. - Т. 8. N 1. - С. 17.

237. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol. Nephrol. 2002; 36(2): 119 - 23.

238. Dyer J, Wyke S, Lynch C. Hospital Episode Statistics data analysis of postoperative venous thromboembolus in patients undergoing urological surgery: a review of 126,891 cases. Ann. R. Coll. Surg. Engl. 2013; 95: 65 - 9.

239. Heiman J., Large T., Krambeck A. Best practice in the management of benign prostatic hyperplasia in the patients requiring anticoagulation. Ther Adv Urol. 2018 Dec; 10(12): 431 - 436.

240. Bejjani BB, Chen DCP, Nolan NG, Edson M. Minidose heparin in transurethral prostatectomy. Urology 1983; 22: 251 - 4.

241. Pushkar D, Vinarov A, Spivak L, Kolontarev K, Putilovskiy M, Andrianova E, Epstein O. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial. Cent European J Urol. 2018; 71(4): 427 - 435. doi: 10.5173/ceju.2018.1803. Epub 2018 Dec 27.

242. Корнеев И.А. "Российский опыт применения суппозиториев Витапрост форте у больных с симптомами нижних мочевых путей и доброкачественной гиперплазией предстательной железы: сравнительный анализ исследований Урология 2017, N 3, стр. 140

243. Vinarov AZ, Aliaev IuG, Apolikhin OI, Mazo EB, Darenkov SP, Demidko IuL, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression. Urologiia. 2010 Nov-Dec; (6): 3 - 10.

244. Vinarov AZ, Spivak LG, Platonova DV, Rapoport LM, Korolev DO. 15-years" survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression. Urologia. 2019 Feb; 86(1): 17 - 22. doi: 10.1177/0391560318772466. Epub 2018 May 9.

245. Enikeev D, Glybochko P, Okhunov Z, Alyaev Y, Rapoport L, Tsarichenko D, Enikeev M, Sorokin N, Dymov A, Taratkin M. Retrospective Analysis of Short-Term Outcomes After Monopolar Versus Laser Endoscopic Enucleation of the Prostate: A Single Center Experience. J Endourol. 2018 May; 32(5): 417 - 423. doi: 10.1089/end.2017.0898. Epub 2018 Mar 13. PMID: 29430969.

246. Gauhar V, Nedbal C, Castellani D, Fong KY, Sofer M, MR, Tursunkulov AN, Ying LK, Elterman D, Mahajan A, Petov V, Ivanovich SN, Bhatia TP, Enikeev D, Gadzhiev N, Chiruvella M, Teoh JY, Galosi AB, Sancha FG, Somani BK, Herrmann TRW. Comparison Between Thulium Fiber Laser and High-power Holmium Laser for Anatomic Endoscopic Enucleation of the Prostate: A Propensity Score-matched Analysis from the REAP Registry. Eur Urol Focus. 2023 Jul 4: S2405-4569(23)00150-5. doi: 10.1016/j.euf.2023.06.009. Epub ahead of print. PMID: 37414615.

247. Enikeev D, Taratkin M, Babaevskaya D, Morozov A, Petov V, Sukhanov R, Shpot E, Misrai V, Chinenov D, Enikeev M, Herrmann T. Randomized prospective trial of the severity of irritative symptoms after HoLEP vs ThuFLEP. World J Urol. 2022 Aug; 40(8): 2047 - 2053. doi: 10.1007/s00345-022-04046-8. Epub 2022 Jun 12. PMID: 35690952.

248. Petov V, Babaevskaya D, Taratkin M, Chuvalov L, Lusuardi L, Misrai V, Sukhanov R, Scoffone CM, Enikeev D. Thulium Fiber Laser Enucleation of the Prostate: Prospective Study of Mid- and Long-Term Outcomes in 1328 Patients. J Endourol. 2022 Sep; 36(9): 1231 - 1236. doi: 10.1089/end.2022.0029. Epub 2022 Aug 2. PMID: 35414204.